Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Q32 Bio Inc. Director's Dealing 2021

Feb 9, 2021

34891_dirs_2021-02-09_5682e0f3-d596-42e2-b334-2d393ad65247.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2021-02-05

Reporting Person: Smith W Bradford (CFO & Treasurer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-02-08 Common Stock M 13500 $0.64 Acquired 13500 Direct
2021-02-08 Common Stock S 13500 $14.2537 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-02-05 Employee Stock Option (Right to Buy) $13.78 A 122000 Acquired 2031-02-05 Common Stock (122000) Direct
2021-02-05 Restricted Stock Units $ A 20000 Acquired Common Stock (20000) Direct
2021-02-08 Employee Stock Option (Right to Buy) $0.64 M 13500 Disposed 2027-04-05 Common Stock (13500) Direct

Footnotes

F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2020.

F2: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $14.00 to $14.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The option vests in 48 equal monthly installments on the first day of each calendar month following January 1, 2021.

F4: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F5: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024.

F6: The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was April 3, 2017.